by Plexium | Jan 16, 2024 | All Posts, Press Releases
San Diego, California, January 16, 2024 – Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Michael Martin, Ph.D. as President and Chief Executive Officer, and a member of the Board of...
by Plexium | Dec 12, 2023 | All Posts, Press Releases
San Diego, California, December 12, 2023 – Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation company, today reported that the first subjects have been dosed in a Phase 1 clinical study of orally administered PLX-4545, a potent and...
by Plexium | Sep 29, 2022 | All Posts, Press Releases
San Diego, California, September 29, 2022 – Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Suzanne Zoumaras as Executive Vice President, Head of Human Resources. Ms. Zoumaras is an...
by Plexium | Jul 13, 2022 | Press Releases
San Diego, California, [July 13, 2022] – Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Brian Wong as a member of its Board of Directors. Dr. Wong is a well-respected leader with more...
by Plexium | May 3, 2022 | Press Releases
San Diego, California, [May 3, 2022] – Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Stephen Mullennix as Chief Financial Officer (CFO). Mr. Mullennix brings more than 20 years of...
by Plexium | Apr 28, 2022 | Press Releases
San Diego, California, [April 28, 2022] – Plexium, Inc. (Plexium) and AbbVie (NYSE: ABBV) have entered into an exclusive strategic collaboration to develop and commercialize novel Targeted Protein Degradation (TPD) therapeutics for neurological conditions. This...